With antibodies accounting for seven out of the top ten global drugs, it is of critical importance that those companies that invest huge sums of money into R&D in this technology space are able to protect their investment from unlawful competition. Hazel Ford and Martin MacLean at Mathys & Squire focus on the European Patent Office (EPO), and on the key issues, you will likely need to address, in order to obtain patent protection in Europe for a new antibody therapeutic.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/10/Patenting-Antibodies-at-the-European-Patent-Office.pdf” width=”100%” height=”900px” style=”border:0;”]